Skip to main content
Top
Published in: Diabetologia 10/2010

01-10-2010 | Article

Beneficial effects of implementing guidelines on microbiology and costs of infected diabetic foot ulcers

Authors: A. Sotto, J.-L. Richard, C. Combescure, N. Jourdan, S. Schuldiner, N. Bouziges, J.-P. Lavigne

Published in: Diabetologia | Issue 10/2010

Login to get access

Abstract

Aims/hypothesis

In 2003, guidelines for management of diabetic foot infection (DFI) were written by the authors’ team according to the guidelines of the International Working Group on the Diabetic Foot. The effects of implementing these guidelines on the microbiology and costs of infected diabetic foot ulcers were assessed.

Methods

From 2003 to 2007, potential beneficial effects of implementing these guidelines were assessed by comparison over time of bacteriological data (number of bacterial samples, number of microorganisms isolated in cultures, prevalence of multidrug-resistant organisms [MDRO] and colonising flora), and costs related to use of antimicrobial agents and microbiology laboratory workload.

Results

The study included 405 consecutive diabetic patients referred to the Diabetic Foot Unit for a suspected DFI. From 2003 to 2007, a significant decrease was observed in the median number of bacteria species per sample (from 4.1 to 1.6), prevalence of MDRO (35.2% vs 16.3%) and methicillin-resistant Staphylococcus aureus (52.2% vs 18.9%) (p < 0.001). Moreover, prevalence of pathogens considered as colonisers dramatically fell from 23.1% to 5.8% of all isolates (p < 0.001). In parallel, implementation of guidelines was associated with a saving of €14,914 (US$20,046) related to a reduced microbiology laboratory workload and €109,305 (US$147,536) due to reduced prescription of extended-spectrum antibiotic agents.

Conclusions/interpretation

Implementation of guidelines for obtaining specimens for culture from patients with DFI is cost-saving and provides interesting quality indicators in the global management of DFI.
Literature
1.
go back to reference American Diabetes Association (1999) Consensus development conference on diabetic foot wound care. Diab Care 22:1354–1360CrossRef American Diabetes Association (1999) Consensus development conference on diabetic foot wound care. Diab Care 22:1354–1360CrossRef
2.
go back to reference American Diabetes Association (2004) Nephropathy in diabetes. Diab Care 27:579–583 American Diabetes Association (2004) Nephropathy in diabetes. Diab Care 27:579–583
4.
go back to reference Barry J, Brown A, Ensor V et al (2003) Comparative evaluation of the VITEK 2 Advanced Expert System (AES) in five UK hospitals. J Antimicrob Chemother 51:1191–1202CrossRefPubMed Barry J, Brown A, Ensor V et al (2003) Comparative evaluation of the VITEK 2 Advanced Expert System (AES) in five UK hospitals. J Antimicrob Chemother 51:1191–1202CrossRefPubMed
5.
go back to reference Berendt AR, Peters EJG, Bakker K et al (2008) Diabetic foot osteomyelitis: a progress report on diagnosis and a systematic review of treatment. Diabetes Metab Res Rev 24:S145–S161CrossRefPubMed Berendt AR, Peters EJG, Bakker K et al (2008) Diabetic foot osteomyelitis: a progress report on diagnosis and a systematic review of treatment. Diabetes Metab Res Rev 24:S145–S161CrossRefPubMed
6.
go back to reference Carlet J, Astagneau P, Brun-Buisson C et al (2009) French national program for prevention of healthcare-associated infections and antimicrobial resistance, 1992–2008: positive trends, but perseverance needed. Infect Control Hosp Epidemiol 30:737–745CrossRefPubMed Carlet J, Astagneau P, Brun-Buisson C et al (2009) French national program for prevention of healthcare-associated infections and antimicrobial resistance, 1992–2008: positive trends, but perseverance needed. Infect Control Hosp Epidemiol 30:737–745CrossRefPubMed
7.
go back to reference Chantelau E, Tanudjaja T, Altenhofer F, Ersanli Z, Lacigova S, Metzger C (1996) Antibiotic treatment for uncomplicated neuropathic forefoot ulcers in diabetes: a controlled trial. Diabet Med 13:156–159CrossRefPubMed Chantelau E, Tanudjaja T, Altenhofer F, Ersanli Z, Lacigova S, Metzger C (1996) Antibiotic treatment for uncomplicated neuropathic forefoot ulcers in diabetes: a controlled trial. Diabet Med 13:156–159CrossRefPubMed
8.
go back to reference Citron DM, Goldstein EJC, Merriam CV, Lipsky BA, Abramson MA (2007) Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. J Clin Microbiol 45:2819–2828CrossRefPubMed Citron DM, Goldstein EJC, Merriam CV, Lipsky BA, Abramson MA (2007) Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. J Clin Microbiol 45:2819–2828CrossRefPubMed
9.
go back to reference Dang CN, Prasad YDM, Boulton AJ, Jude EB (2003) Methicillin-resistant Staphylococcus aureus in the diabetic foot clinic: a worsening problem. Diabet Med 20:159–161CrossRefPubMed Dang CN, Prasad YDM, Boulton AJ, Jude EB (2003) Methicillin-resistant Staphylococcus aureus in the diabetic foot clinic: a worsening problem. Diabet Med 20:159–161CrossRefPubMed
10.
go back to reference European Antimicrobial Resistance Surveillance System (EARSS), Antibiotic Susceptibility Testing (2010). The European Antimicrobial Resistance Surveillance System. Available from www.rivm.nl/earss, accessed 4 February 2010 European Antimicrobial Resistance Surveillance System (EARSS), Antibiotic Susceptibility Testing (2010). The European Antimicrobial Resistance Surveillance System. Available from www.​rivm.​nl/​earss, accessed 4 February 2010
11.
go back to reference French National Observatory for Epidemiology of Bacterial Resistance to Antimicrobials (2010) Onerba. Available from www.onerba.org, accessed 4 February 2010 French National Observatory for Epidemiology of Bacterial Resistance to Antimicrobials (2010) Onerba. Available from www.​onerba.​org, accessed 4 February 2010
12.
go back to reference International Working Group on the Diabetic Foot, International Consensus on the diabetic foot (1999) International Working Group on the Diabetic Foot. Available from www.iwgdf.org, accessed 4 February 2010 International Working Group on the Diabetic Foot, International Consensus on the diabetic foot (1999) International Working Group on the Diabetic Foot. Available from www.​iwgdf.​org, accessed 4 February 2010
13.
go back to reference Jeffcoate WJ, Lipsky BA, Berendt AR et al (2008) Unresolved issues in the management of ulcers of the foot in diabetes. Diabet Med 25:1380–1389CrossRefPubMed Jeffcoate WJ, Lipsky BA, Berendt AR et al (2008) Unresolved issues in the management of ulcers of the foot in diabetes. Diabet Med 25:1380–1389CrossRefPubMed
14.
go back to reference Leclercq R (2009) Epidemiological and resistance issues in multidrug-resistant staphylococci and enterococci. Clin Microbiol Infect 15:224–231CrossRefPubMed Leclercq R (2009) Epidemiological and resistance issues in multidrug-resistant staphylococci and enterococci. Clin Microbiol Infect 15:224–231CrossRefPubMed
15.
go back to reference Lelievre H, Lina G, Jones ME et al (1999) Emergence and spread in French hospitals of methicillin-resistant Staphylococcus aureus with increasing susceptibility to gentamicin and other antibiotics. J Clin Microbiol 37:3452–3457PubMed Lelievre H, Lina G, Jones ME et al (1999) Emergence and spread in French hospitals of methicillin-resistant Staphylococcus aureus with increasing susceptibility to gentamicin and other antibiotics. J Clin Microbiol 37:3452–3457PubMed
16.
17.
go back to reference Lipsky BA (2004) International consensus group on diagnosing and treating the infected diabetic foot: a report from the international consensus on diagnosing and treating the infected diabetic foot. Diabetes Metab Res Rev 20:S68–S77CrossRefPubMed Lipsky BA (2004) International consensus group on diagnosing and treating the infected diabetic foot: a report from the international consensus on diagnosing and treating the infected diabetic foot. Diabetes Metab Res Rev 20:S68–S77CrossRefPubMed
18.
go back to reference Lipsky BA, Berendt AR, Deery HG et al (2004) Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 39:885–910CrossRefPubMed Lipsky BA, Berendt AR, Deery HG et al (2004) Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 39:885–910CrossRefPubMed
19.
go back to reference Lipsky BA, Stoutenburgh U (2005) Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother 55:240–245CrossRefPubMed Lipsky BA, Stoutenburgh U (2005) Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother 55:240–245CrossRefPubMed
20.
go back to reference Monnet DL, Molstad S, Cars O (2004) Defined daily doses of antimicrobials reflect antimicrobial prescriptions in ambulatory care. J Antimicrob Chemother 53:1109–1111CrossRefPubMed Monnet DL, Molstad S, Cars O (2004) Defined daily doses of antimicrobials reflect antimicrobial prescriptions in ambulatory care. J Antimicrob Chemother 53:1109–1111CrossRefPubMed
21.
go back to reference Pittet D, Hugonnet S, Harbarth S et al (2000) Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. Lancet 356:1307–1312CrossRefPubMed Pittet D, Hugonnet S, Harbarth S et al (2000) Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. Lancet 356:1307–1312CrossRefPubMed
22.
go back to reference Prompers L, Huijberts M, Schaper N et al (2008) Resource utilisation and costs associated with the treatment of diabetic foot ulcers. Prospective data from the Eurodiale study. Diabetologia 51:1826–1834CrossRefPubMed Prompers L, Huijberts M, Schaper N et al (2008) Resource utilisation and costs associated with the treatment of diabetic foot ulcers. Prospective data from the Eurodiale study. Diabetologia 51:1826–1834CrossRefPubMed
23.
24.
go back to reference Richard JL, Sotto A, Jourdan N et al (2008) Risk factors for and impact on healing of multidrug-resistant bacteria in diabetic foot ulcers. Diab Metab 34:363–369CrossRef Richard JL, Sotto A, Jourdan N et al (2008) Risk factors for and impact on healing of multidrug-resistant bacteria in diabetic foot ulcers. Diab Metab 34:363–369CrossRef
25.
go back to reference Slater RA, Lazarovitch T, Boldur I et al (2004) Swab cultures accurately identify pathogens in diabetic foot wounds not involving bone. Diabet Med 21:705–709CrossRefPubMed Slater RA, Lazarovitch T, Boldur I et al (2004) Swab cultures accurately identify pathogens in diabetic foot wounds not involving bone. Diabet Med 21:705–709CrossRefPubMed
26.
go back to reference Société de Pathologie Infectieuse de Langue Française (2007) Management of diabetic foot infections. Méd Mal Infect 37:1–25 Société de Pathologie Infectieuse de Langue Française (2007) Management of diabetic foot infections. Méd Mal Infect 37:1–25
27.
go back to reference Sotto A, Lina G, Richard JL et al (2008) Virulence potential of Staphylococcus aureus strains isolated from diabetic foot ulcers: a new paradigm. Diab Care 31:2318–2324CrossRef Sotto A, Lina G, Richard JL et al (2008) Virulence potential of Staphylococcus aureus strains isolated from diabetic foot ulcers: a new paradigm. Diab Care 31:2318–2324CrossRef
28.
go back to reference Soussy CJ, Carret G, Cavallo JD and the Antibiotic Susceptibility Testing Committee of the French Society for Microbiology, Antibiotic Susceptibility Testing (2010) French Society for Microbiology. Available from www.sfm.asso.fr, accessed 4 February 2010 Soussy CJ, Carret G, Cavallo JD and the Antibiotic Susceptibility Testing Committee of the French Society for Microbiology, Antibiotic Susceptibility Testing (2010) French Society for Microbiology. Available from www.​sfm.​asso.​fr, accessed 4 February 2010
29.
go back to reference Tentolouris N, Petrokkos G, Vallianou N et al (2006) Prevalence of methicillin-resistant Staphylococcus aureus in infected and uninfected diabetic foot ulcers. Clin Microbiol Infect 12:186–189CrossRefPubMed Tentolouris N, Petrokkos G, Vallianou N et al (2006) Prevalence of methicillin-resistant Staphylococcus aureus in infected and uninfected diabetic foot ulcers. Clin Microbiol Infect 12:186–189CrossRefPubMed
Metadata
Title
Beneficial effects of implementing guidelines on microbiology and costs of infected diabetic foot ulcers
Authors
A. Sotto
J.-L. Richard
C. Combescure
N. Jourdan
S. Schuldiner
N. Bouziges
J.-P. Lavigne
Publication date
01-10-2010
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 10/2010
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-010-1828-3

Other articles of this Issue 10/2010

Diabetologia 10/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.